Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Trimmed by Diametric Capital LP

Diametric Capital LP trimmed its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 39.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,728 shares of the company’s stock after selling 6,995 shares during the period. Diametric Capital LP’s holdings in Day One Biopharmaceuticals were worth $136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of DAWN. R Squared Ltd purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $31,000. E Fund Management Co. Ltd. bought a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $143,000. KLP Kapitalforvaltning AS bought a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $150,000. XTX Topco Ltd bought a new stake in Day One Biopharmaceuticals in the third quarter worth approximately $178,000. Finally, Teacher Retirement System of Texas lifted its holdings in Day One Biopharmaceuticals by 20.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock worth $226,000 after purchasing an additional 3,086 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. HC Wainwright decreased their price target on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Wedbush reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.29.

Day One Biopharmaceuticals Trading Up 4.7 %

Shares of NASDAQ DAWN opened at $7.97 on Thursday. The company has a fifty day moving average price of $10.32 and a 200 day moving average price of $12.47. Day One Biopharmaceuticals, Inc. has a 1-year low of $7.28 and a 1-year high of $18.07. The firm has a market cap of $807.80 million, a PE ratio of -7.74 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. Equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This represents a 10.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock worth $251,925 in the last three months. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.